# Takeda Study Shows Entyvio Lowers Ulcerative Colitis Complication Risk by 67 Percent

- URL: https://stocks.freetheai.org/news/takeda-study-shows-entyvio-lowers-ulcerative-colitis-complication-risk-by-67-1ff76b
- Published: 2026-10-19T09:30:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [TSE:4502](https://stocks.freetheai.org/symbols/TSE-4502)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Takeda Pharmaceutical Company Limited (TSE:4502) reported Phase 4 trial results showing that its drug Entyvio significantly delayed ulcerative colitis complications when targeting full disease clearance. Patients achieving treat-to-target disease clearance experienced a 67% lower risk of first colitis-related complications compared to those reaching only symptomatic remission. In the study, 57% of participants attained disease clearance by Week 16.

The trial findings validate deeper disease clearance as a clinical target in treating moderate to severe ulcerative colitis, offering evidence that moving beyond symptom control can improve long-term outcomes. Additionally, the drug's safety profile remained consistent with earlier data over 96 weeks, showing no new safety concerns. Takeda stock traded slightly higher following the announcement, rising 0.34% to 6,244 JPY.

Investors and medical practitioners will watch for potential updates to clinical treatment guidelines, potential changes to drug labels, and shifts in healthcare payer coverage that explicitly recognize treat-to-target disease clearance.

## Key points

- Entyvio reduced the risk of ulcerative colitis complications by approximately 67% compared to symptomatic remission alone.
- In the Phase 4 VERDICT trial, 57% of patients reached target disease clearance by Week 16.
- Safety results through 96 weeks remained consistent with prior studies, with no new safety signals observed.
- Potential future catalysts include clinical guideline updates, drug label revisions, and payer coverage shifts.

## Questions and answers

### How effective was Entyvio in reducing ulcerative colitis complications?

Results from Takeda's Phase 4 VERDICT trial showed Entyvio reduced the risk of first colitis-related complications by approximately 67% when targeting disease clearance compared to symptomatic remission alone.

### Were there any new safety concerns in the Entyvio Phase 4 trial?

No new safety signals were identified. Entyvio's safety profile over 96 weeks remained consistent with findings from previous clinical studies.

### What percentage of patients achieved disease clearance with Entyvio by Week 16?

In the Phase 4 trial, 57% of achieving patients reached target disease clearance by Week 16.